United States-based Harmony Biosciences Holdings Inc. (Nasdaq: HRMY) has received approval from the United States Food and Drug Administration (FDA) for WAKIX (pitolisant) intended for the treatment of cataplexy in adult patients with narcolepsy, it was reported on Wednesday.
The product is the first and only treatment approved by the US FDA for patients with excessive daytime sleepiness or cataplexy associated with narcolepsy that is not scheduled as a controlled substance by the US Drug Enforcement Administration (DEA).
IT is a first-in-class medication and a selective histamine 3 (H3) receptor antagonist/inverse agonist that works via a novel mechanism of action to increase the synthesis and release of histamine. It is administered orally, once daily in the morning upon wakening. FDA approval of WAKIX for the treatment of cataplexy in adult patients with narcolepsy is based on the results from two randomised, controlled trials (HARMONY CTP and HARMONY 1) from the clinical development program for WAKIX.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT